Sanofi Abandons Deal for Rare Disease Drug Amid FTC’s Monopoly Concerns
Sanofi is walking away from a deal to license an experimental Maze Therapeutics drug for a rare enzyme deficiency after the Federal Trade Commission challenged the transaction as anti-competitive. The…
Read More »
FTC’s New Rule on Reviews in Marketplaces
Related Practices & Jurisdictions Wednesday, August 16, 2023 At the end of June 2023, the FTC proposed a new rule targeted at deceptive reviews in the marketplace. The proposed rule would prohibit…
Read More »